were cotransfected with GSK-3␤ wild-type (wt) and CRMP-2 wt and subjected to immunoblot analysis with anti-CRMP-2 antibody ( Figure 1B) . The mobility shift of CRMP-2 (asterisk) was observed in the cells cotransfected with GSK-3␤ wt and CRMP-2 wt. We then produced the antibody that specifically recognized phosphorylated CRMP-2 at Thr-514 (anti-pT514 antibody). In the COS7 cells cotransfected with CRMP-2 wt and GSK-3␤ wt, anti-pT514 antibody recognized the upper bands, which corresponded to the phosphorylated CRMP-2 at Thr-514. In contrast, the immunoreactive band was not observed in runs with CRMP-2 T514A (Thr-514 was replaced by Ala) and GSK-3␤ wt. Consistent with the result using anti-pT514 antibody, the mobility shift of CRMP-2 (asterisk) was not observed in these cells. These results suggest that GSK-3␤ phosphorylates CRMP-2 at Thr-514.
Next, we examined whether GSK-3␤ phosphorylates CRMP-2 at Thr-514 in vitro ( Figure 1C ). The phosphorylation of CRMP-2 at Thr-514 was not observed when GSK-3␤ alone was added. GSK-3␤ requires prephosphorylation of its substrate (Eldar-Finkelman, 2002). CRMP-2 has a consensus motif recognized by Cdk5 at Ser-522 in the vicinity of the phosphorylation site of GSK-3␤, Thr-514. We found that GSK-3␤ phosphorylated CRMP-2 that was prephosphorylated by Cdk5 in vitro. When Cdk5 alone was added, CRMP-2 at Thr-514 was not phosphorylated. These results indicate that GSK-3␤ can phosphorylate CRMP-2 at Thr-514 after CRMP-2 is phosphorylated by Cdk5.
We then evaluated each phosphorylation site (Thr-514, Ser-518, and Ser-522). Not only CRMP-2 T514A but also S518A (Ser-518 was replaced by Ala), S522A (Ser-522 was replaced by Ala), and AAA (Thr-514, Ser-518, and Ser-522 were replaced by Ala) blocked the band shift of CRMP-2 (see Supplemental Figure S1A at http:// www.cell.com/cgi/content/full/120/1/137/DC1/). Consistently, the band immunoreactive with anti-pT514 antibody was not observed in runs with T514A, S518A, S522A, and AAA. It is reported that the phosphorylation of CRMP-2 at Thr-514 but not Ser-518 or Ser-522 induces the mobility shift of CRMP-2 (Gu et al., 2000). These results suggest that Ser-518 and Ser-522 are re- We examined whether CRMP-2 is phosphorylated by lated by GSK-3␤ at Thr-514 ( Figure 1A) . To examine whether GSK-3␤ phosphorylates CRMP-2, COS7 cells GSK-3␤ in hippocampal neurons during axon outgrowth. The immunoblot analysis with anti-pT514 antibody re-(phosphorylated CRMP-2, red) and anti-CRMP-2 antibodies (total CRMP-2, green; Figure 2B ). CRMP-2 vealed that CRMP-2 was phosphorylated at Thr-514 in hippocampal neurons at 3 DIV (more than 75% of neu-(green) was enriched in the distal part of the growing axon as previously reported (Inagaki et al., 2001). Phosrons at stage 3; Figure 2A ). About 30% of CRMP-2 was constitutively phosphorylated at Thr-514. When hippophorylated CRMP-2 at Thr-514 (red) was enriched in the distal part of the growing axon without growth cone. campal neurons were cultured in the presence of GSK-3 inhibitors (LiCl, SB216763, or SB415286), the phosphorThe merged images of CRMP-2 and phosphorylated CRMP-2 at Thr-514 immunofluorescence enable us to ylation levels of CRMP-2 at Thr-514 were decreased. Cdk inhibitor (olomoucine) also decreased the phosroughly estimate the phosphorylation levels of CRMP-2. The merged image in the shaft was yellow, whereas that phorylation levels of CRMP-2 at Thr-514 (see Supplemental Figure S1B on the Cell web site). These results in the axonal growth cone was more greenish than that in the shaft. Thus, the ratio of phosphorylated CRMP-2 suggest that GSK-3␤ phosphorylates CRMP-2 at Thr-514 after CRMP-2 is phosphorylated by Cdk5 in hippoto total CRMP-2 in the axonal growth cone was lower than that in the shaft. campal neurons.
To investigate the spatial distribution of phosphoryFurther, clear evidence was obtained by intensity imaging of phosphorylated CRMP-2 and total CRMP-2 lated CRMP-2 at Thr-514, hippocampal neurons were fixed at 3 DIV and then immunostained with anti-pT514 ( Figure 2B ). The intensity imaging was similar in shafts, Figure S1C) . wt, whereas CRMP-2 T514D had the weaker activity. These results are consistent with the observation that CRMP-2 T514D showed lower activity to interact with Phosphorylation of CRMP-2 Lowers its Activity tubulin. CRMP-2 S518A, S522A, and AAA promoted for Interaction with Tubulin axon outgrowth as well as CRMP-2 T514A (SupplemenWe recently found that the phosphorylation of CRMP-2 tal Figure S2A ). (Figures 5D and 5E ). GSK-3␤
To examine the effect of NT-3 on the spatial distribution of phosphorylated CRMP-2 at Thr-514, hippocam-S9A showed slightly higher activity than GSK-3␤ wt in this capacity. GSK-3␤ KD had no obvious effect. The pal neurons were fixed at 3 DIV after the treatment of NT-3 for 30 min and then immunostained with anti-pT514 consistent results were obtained by using other axonal markers, such as synapsin I and synaptophysin for axon (phosphorylated CRMP-2, red) and anti-CRMP-2 antibodies (total CRMP-2, green; Figure 6C ). The phosphor-(Supplemental Figure S3C) . Further, the effect of GSK-3␤ S9A on axon formation was examined at 6 DIV, and the ylation levels of CRMP-2 at Thr-514 (red) were decreased not only in the axonal growth cone but also in consistent results were obtained (Supplemental Figure  S3D) . These results suggest that the overexpression of the shaft as compared with nontreated cells (Figures 2B  and 6C ). In the cell body, the obvious decrease of the GSK-3␤ impairs neuronal polarity, presumably by suppressing neurite elongation. phosphorylation levels of CRMP-2 was not observed. We then examined whether CRMP-2 is involved in Next, we investigated whether the expression of the nonphosphorylated form of CRMP-2 compensates for NT-3-and BDNF-induced axon outgrowth and branching. NT-3 and BDNF promoted axon elongation and the GSK-3␤-induced defect. The expression of CRMP-2 wt or CRMP-2 T514A counteracted the effects of GSK-3␤ branching as previously described (Tucker [2002] ; Figures 6D and 6E) . We used siRNA to directly test whether S9A on axon outgrowth and neuronal polarity ( Figure  5F ), but CRMP-2 T514D had no obvious effects (data endogenous CRMP-2 is required for axon elongation and branching by NT-3 and BDNF ( Figure 6E ). Expresnot shown). Taken together, these results suggest that GSK-3␤ regulates neuronal polarity through the phossion of CRMP-2 was markedly inhibited by CRMP-2 siRNA in 10%-20% cells as revealed by immunocytophorylation of CRMP-2, though we can not neglect the possibility that GSK-3␣ is involved in neuronal polarity. Figure 1C ). GSK-3␤ requires a priming phosphate to phorylation levels of CRMP-2 at Ser-522 and thereby promote growth cone collapse. phosphorylate its substrates. CRMP-2 has a consensus motif recognized by Cdk5 at Ser-522 in the vicinity of Thr-514 ( Figure 1A) . We found that treatment of Cdk Neuronal Polarity and GSK-3␤ Previously, we found that CRMP-2 is crucial for deinhibitor (olomoucine) decreased the phosphorylation levels of CRMP-2 in COS7 cells (data not shown) and termining the fate of the axon and dendrites, thereby establishing and maintaining neuronal polarity (Inagaki hippocampal neurons (Supplemental Figure S1B) and that GSK-3␤ phosphorylated CRMP-2 that was preet al., 2001). CRMP-2 appears to be critical for axon formation by promoting elongation of one of the immaphosphorylated by Cdk5 in vitro ( Figure 1C) . Therefore, it is likely that Cdk5 phosphorylates CRMP-2 at Serture neurites, which is the future axon and within which CRMP-2 is enriched. CRMP-2 binds to tubulin hetero-522, whereby GSK-3␤ phosphorylates CRMP-2 at Thr-514 in vivo. Ser-518 is also a potential phosphorylation dimers and promotes microtubule assembly to enhance axon growth and branching (Fukata et al., 2002) . Resite of CRMP-2 by GSK-3␤.
chemistry as described (Nishimura et al. [2003]; data not shown). Knockdown of CRMP-2 caused a marked inhibition of NT-3-and BDNF-induced axon elongation
Phosphomimic CRMP-2 was not colocalized with the cently, it has been reported that the polarized distributions of PAR-3/PAR-6 and aPKC activity are important mitotic spindle in vivo ( Figure 3A, Supplemental Figure  S1D ). Phosphorylated CRMP-2 at Thr-514 was not assofor axon specification in hippocampal neurons and that the PI3-kinase activity at the axon is required for polarciated with the mitotic spindle ( Figure 3B We also found that the inhibitory effect of GSK-3␤ on formation of degenerating neurites in Alzheimer's disease (Gu et al., 2000) . Phosphorylated CRMP-2 was neuronal polarity is counteracted by nonphosphorylated CRMP-2 ( Figure 5F ). Taken together, these results indiidentified as an antigen for 3F4 monoclonal antibody, which was raised against partially purified paired helical cate that GSK-3␤ regulates neuronal polarity through the phosphorylation of CRMP-2. filaments and labeled neurofibrillary tangles and some plaque neurites. The level of 3F4 antigen is increased in We propose the role of GSK-3␤ and CRMP-2 in axon specification as follows (Figure 7) . The activation of PI3-the soluble fraction of the brains affected by Alzheimer's disease. These observations raise the possibility that kinase at the selective immature neurite produces PIP 3 , thus activating Akt and recruiting the PAR-3/PAR-6/ hyperphosphorylation of CRMP-2 is involved in the development of neurofibrillary tangles and plaque neurites. aPKC complex at the growth cone. Activated Akt and aPKC inhibit GSK-3␤ by its phosphorylation, whereby Inhibition of GSK-3␤ prevents semaphorin-3A (Sema3A)-induced growth cone collapse (Eickholt et al., 2002) . 
Plasmid Constructs
plemented with B-27 supplement (Invitrogen) and 1 mM glutamine. Neurons were seeded on coverslips with PDL only for 6 DIV to CRMP-2 mutants were generated with a site-detected mutagenesis kit (Stratagene, La Jolla, CA). The cDNA fragments encoding visualize secondary axons. Neurons were transfected using a calcium phosphate method before plating to analyze the morphology CRMP-2 wt and mutants were subcloned into pRSET-C1 (Invitrogen, Carlsbad, CA) to obtain the construct of CRMP-2 tagged with histi- (Nishimura et al., 2003; Menager et al., 2004) . Neurons were fixed at 3 DIV or 6 DIV with 3.7% formaldehyde in PBS for 10 min at room dine (His) at the N terminus of protein, pB-GEX (rearranged vector from pGEX; Amersham Pharmacia Biotech, Buckinghamshire, UK) temperature, followed by treatment for 10 min with 0.05% Triton X-100 on ice and 10% NGS in PBS for 1 hr at room temperature. to obtain the construct of CRMP-2 tagged with GST at the C terminus of protein, pCAGGS-myc, and pEGFP-C1 (Clontech, Palo Alto, CA)
Neurons were then immunostained with indicated antibodies and observed with a confocal laser microscope (LSM510 Carl Zeiss, vectors, respectively. pCGN-GSK-3␤, pCGN-GSK-3␤ S9A, and pCGN-GSK-3␤ kinase dead (KD; K85N) and pGEX-2T-GSK-3␤ were Oberkochen, Germany) built around an Axiovert 100 M (Carl Zeiss). The length of a longest neurite was measured as that of an axon at constructed as described by Tanji et al. (2002) . All fragments were confirmed by DNA sequencing.
3 DIV. The percentage of neurons with the second longest neurite whose length was longer than a half-length of the longest neurite was counted as that of multiple long neurites. Neurotrophins were Protein Purification and Preparation of Anti-pT514 Antibody added to the medium at a concentration of 100 ng/ml after the GST-and His-tagged proteins were purified from E. coli on glutathitransfection. Neurons were cultured for 2 days and were then grown one-Sepharose 4B beads (Amersham) and Ni-NTA agarose (Qiagen, with fresh neurotrophins (100 ng/ml) for 1 day. For some experiHilden, Germany) according to the manufacturers' protocols. Rabbit ments, neurons were treated with 10% (w/v) TCA. The resulting polyclonal antibody against CRMP-2 phosphorylated at Thr-514 precipitates were subjected to SDS-PAGE and immunoblot analysis. (anti-pT514 antibody) was raised as described by Amano et al. 
